TARA
Protara Therapeutics, Inc.
$4.11
-0.16 (-3.75%)
At close · Jul 8
Market Cap
$231.00M
Shares
56,204,237
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.95M
FY2014
Net Income
-$57.44M
-28.8%
FY2025
Operating Margin
-257.12%
FY2014
Diluted EPS
-$1.34
+38.2%
FY2025
Operating Cash Flow
-$56.37M
-57.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | $2.95M | — | — | |
| -$174K | — | — | — | — | — | -$34K | — | — | — | — | — | — | — | — | |
| $47.05M | $42.63M | $31.7M | $24.99M | $16.81M | $21.09M | $11.98M | $3.88M | $11.85M | $21.69M | $18.87M | $12.38M | $6.43M | $3.99M | $5.91M | |
| $23.01M | $21.92M | $17.45M | $18.62M | $20.74M | $26.4M | $22.46M | $3.95M | $9.52M | $8.68M | $9.84M | $8.49M | $4.1M | $3.13M | $2.09M | |
| — | — | — | — | — | — | — | — | — | — | $123K | $57K | $30K | $27K | $57K | |
| — | — | — | — | — | — | — | $2.85M | — | — | — | — | — | — | — | |
| $70.05M | $64.55M | $49.15M | $43.61M | $67.06M | $47.49M | $34.44M | $7.83M | $21.37M | $30.36M | $28.71M | $20.87M | $10.53M | $7.12M | $8M | |
| -$70.05M | -$64.55M | -$49.15M | -$43.61M | -$67.06M | -$47.49M | -$34.44M | -$7.83M | -$21.37M | -$30.36M | -$28.71M | -$20.87M | -$7.58M | -$7.12M | -$8M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -257.12% | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$28.58M | -$20.81M | -$7.55M | -$7.1M | -$7.94M | |
| — | — | — | — | — | $0 | $34K | — | — | — | — | — | $857K | $861K | — | |
| $6.5M | $6.38M | $4.17M | $3.19M | $1.11M | $237K | $500K | — | — | — | — | — | — | — | — | |
| $6.75M | $7.11M | $4.56M | $3.19M | $1.11M | $237K | $466K | $262K | $643K | $398K | $179K | -$507K | $4.24M | -$790K | $26K | |
| — | $57.35M | $44.56M | — | — | — | — | -$14.99M | -$20.73M | -$29.96M | -$28.53M | -$21.38M | -$3.34M | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -$110K | $92K | -$140K | |
| -$63.31M | -$57.44M | -$44.6M | -$40.42M | -$65.95M | -$47.25M | -$33.98M | -$7.83M | -$20.73M | -$29.96M | -$28.53M | -$21.38M | -$3.34M | -$7.91M | -$7.97M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -113.36% | — | — | |
| — | — | — | -$40.42M | -$65.95M | $47.25M | $33.98M | — | -$20.73M | -$36.71M | -$28.53M | -$21.38M | -$9.7M | -$14.03M | -$14.1M | |
| -$63.76M | -$57.35M | -$44.56M | -$39.76M | -$66.43M | -$47.46M | -$33.98M | -$14.99M | -$20.71M | -$29.98M | -$28.52M | -$21.38M | -$3.35M | -$7.91M | — | |
| USD/shares | — | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.34 | -$2.17 | -$3.57 | -$5.86 | -$4.21 | — | — | — | — | — | — | — | — | — |
| shares | — | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M | 2.58M | 452.56K | 431.86K | 414.04K | 411.6K | 76.61K | 5879.6 | 5765.175 |
| shares | — | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M | 7.23M | 2.58M | 452.56K | 431.86K | 414.04K | 411.6K | 76.61K | 5879.6 | 5765.175 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $409K in buybacks.
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | -$64,549,000 | -$49,154,000 |